<DOC>
	<DOCNO>NCT00406055</DOCNO>
	<brief_summary>The purpose study 1 ) Provide additional information commercially available Abbott Vascular Carotid Stent Systems Embolic Protection Systems use successfully wide range physician commercial use condition . 2 ) Provide ongoing post-market surveillance mechanism documentation clinical outcome possible extension Centers Medicare Medicaid Services ( CMS ) coverage broad group patient .</brief_summary>
	<brief_title>CHOICE : Carotid Stenting For High Surgical-Risk Patients</brief_title>
	<detailed_description>The CHOICE study provide mechanism collection data Abbott Vascular 's Carotid Stent Systems Embolic Protection Systems use broad group physicians commercial use condition . The original CAPTURE EXACT study built-in feature limit ability collect on-going real world data restrict number site could participate ( 150 site ) limit enrollment site ( 50 patient per site ) . This study restriction . The CHOICE study also provide ongoing post-market surveillance mechanism documentation clinical outcome possible extension Centers Medicare Medicaid Services ( CMS ) coverage broad group patient .</detailed_description>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<criteria>1 . Patient patient 's legally authorize representative provide informed consent . 2 . Patient consider high risk carotid endarterectomy ( CEA ) . 3 . Patient require percutaneous carotid angioplasty stenting carotid artery disease . 4 . Patients physician intend use RX Acculink either RX Accunet Emboshield Nav 6 carotid artery OR patient physician intend use Xact Emboshield Emboshield Nav6 carotid artery per FDA approve Indications Use outline . There exclusion criterion study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>